NCT04125524 is a clinical trial of Terahertz metamaterials in Malignant Tumour, sponsored by Durham University.

Who is sponsoring NCT04125524?

NCT04125524 is sponsored by Durham University.

What drugs are being tested in NCT04125524?

Interventions in NCT04125524: Terahertz metamaterials.

What condition does NCT04125524 study?

NCT04125524 studies Malignant Tumour.

Is NCT04125524 still recruiting?

NCT04125524 is currently suspended. Last updated 1 November 2023.

Last reviewed 2023-11-01 · How we verify

NCT04125524

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Terahertz Metamaterials for Tumour Marker Concentration Identification

Suspended Last updated 1 November 2023

What this trial tests

trial testing Terahertz metamaterials in Malignant Tumour in 90 participants. Suspended.

Timeline

17 May 2021

Primary endpoint
1 October 2022

1 October 2025

Quick facts

Lead sponsor	Durham University
Status	Suspended
Study type	OBSERVATIONAL
Enrollment	90
Start date	17 May 2021
Primary completion	1 October 2022
Estimated completion	1 October 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Terahertz metamaterials

Conditions studied

Malignant Tumour — all drugs for Malignant Tumour →

Sponsor

Durham University

Who can join

Adults 18 to 100, any sex, with Malignant Tumour. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research the investigators plan to undertake involves the use of a metamaterial at terahertz frequencies. Serum samples will be tested using the metamaterial to determine if this method can be used to measure the concentration of tumour markers present in the sample. Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will be used for both the positive and negative samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Malignant Tumour

Currently open trials in the same condition.

NCT06995976 — Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 · EARLY_PHASE1 · recruiting

Other Durham University trials

Trials by the same sponsor.

NCT05981482 — Visual Perception Difficulties After Stroke · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04125524 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Durham University
Last refreshed: 1 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing